局限期小细胞肺癌胸部放射治疗的研究进展

doi:10.13481/j.1671-587x.20180138

[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J]. J Clin Oncol,2006,24(28):4539-4544.
[2] Byers LA,Rudin CM.Small cell lung cancer:where do we go from here[J].Cancer,2015,121(5):664-672.
[3] Micke P,Faldum A,Metz T,et al.Staging small cell lung cancer:Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease[J].Lung Cancer,2002,37(3):271-276.
[4] Shepherd FA,Crowley J,Van Houtte P,et al.The International Association for the Study of Lung Cancer lung cancer staging project:proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor,node,metastasis classification for lung cancer[J].J Thorac Oncol,2007,2(12):1067-1077.
[5] Ignatius Ou SH,Zell JA.The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition[J].J Thorac Oncol,2009,4(3):300-310.
[6] Vallières E,Shepherd FA,Crowley J,et al.The IASLC Lung Cancer Staging Project:proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer[J].J Thorac Oncol,2009,4(9):1049-1059.
[7] Goldstraw P,Crowley J,Chansky K,et al.The IASLC Lung Cancer Staging Project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J].J Thorac Oncol,2007,2(8):706-714.
[8] Almquist D,Mosalpuria K,Ganti AK,et al.Multimodality therapy for limited-stage small-cell lung cancer[J].J Oncol Pract,2016,12(2):111-117.
[9] Verma V,Simone CB,Zhen W.Stereotactic radiotherapy for stage Ⅰ small cell lung cancer[J].Oncologist,2016,21(2):131-133.
[10] Alvarado-Luna G,Morales-Espinosa D.Treatment for small cell lung cancer,where are we now?-a review[J].Transl Lung Cancer Res,2016,5(1):26-38.
[11] Turrisi AT,Kim K,Blum R,et al.Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J].N Engl J Med,1999,340(4):265-271.
[12] El Sharouni SY,Kal HB,Barten-Van Rijbroek A,et al.Concurrent versus sequential chemotherapy and radiotherapy in limited disease small cell lung cancer:a retrospective comparative study[J].Anticancer Res,2009,29(12):5219-5224.
[13] Pignon JP,Arriagada R,Ihde DC,et al.A meta-analysis of thoracic radiotherapy for small-cell lung cancer[J].N Engl J Med,1992,327(23):1618-1624.
[14] Warde P,Payne D.Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis[J].J Clin Oncol,1992,10(6):890-895.
[15] Pijls-Johannesma M,De Ruysscher D,Vansteenkiste J,et al.Timing of chest radiotherapy in patients with limited stage small cell lung cancer:a systematic review and meta-analysis of randomised controlled trials[J].Cancer Treat Rev,2007,33(5):461-473.
[16] De Ruysscher D,Pijls-Johannesma M,Bentzen SM,et al.Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer[J].J Clin Oncol,2006,24(7):1057-1063.
[17] Murray N,Coy P,Pater JL,et al.Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer.The National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,1993,11(2):336-344.
[18] De Ruysscher D,Lueza B,Le Péchoux C,et al.Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:usefulness of the individual patient data meta-analysis[J].Ann Oncol,2016,27(10):1818-1828.
[19] Lueza B,LePéchoux C,Pignon JP,et al.Phase Ⅲ trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small-cell lung cancer[J].Ann Oncol,2014,25(9):1865-1866.
[20] 刘维帅,赵路军,关勇,等.局限期小细胞肺癌诱导化疗疗效与放疗时机的关系探讨[J].中国肿瘤临床,2014,41(1):73-77.
[21] De Ruysscher D,Bremer RH,Koppe F,et al.Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer:a phase Ⅱ trial[J].Radiother Oncol,2006,80(3):307-312.
[22] Baas P,Belderbos JS,Senan S,et al.Concurrent chemotherapy (carboplatin,paclitaxel,etoposide) and involved-field radiotherapy in limited stage small cell lung cancer:a Dutch multicenter phase Ⅱ study[J].Br J Cancer,2006,94(5):625-630.
[23] Hu X,Bao Y,Zhang L,et al.Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer:interim analysis of a prospective randomized noninferiority trial[J].Cancer,2012,118(1):278-287.
[24] Xia B,Chen GY,Cai XW,et al.Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer[J]. Radiother Oncol,2012,102(2):258-262.
[25] Faivre-Finn C,Snee M,Ashcroft L,et al.Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label,phase 3,randomised,superiority trial[J].Lancet Oncol,2017,18(8):1116-1125.
[26] Ulger S,Demirci NY,Aydinkarahaliloglu E,et al.PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancer[J].J Thorac Dis,2015,7(3):295-302.
[27] Cai S,Shi A,Yu R,et al.Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy[J].Radiat Oncol,2014,9:17.
[28] Zhu L,Zhang S,Xu X,et al.Increased biological effective dose of radiation correlates with prolonged survival of patients with limited-stage small cell lung cancer:A systematic review[J].PLoS One,2016,11(5):e0156494.
[29] Xia B,Chen GY,Cai XW,et al.The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer[J].Radiat Oncol,2011,6:50.
[30] Zahra A,Chang T,Hejleh TA,et al.Once daily high-dose radiation (≥ 60 Gy) treatment in limited stage small cell lung cancer[J].J Oncol Transl Res,2016,2(1).pii:108.
[31] Salama JK,Hodgson L,Pang H,et al.A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy:CALGB 30904[J].J Thorac Oncol,2013,8(8):1043-1049.
[32] Lee KJ,Lee EJ,Hur GY,et al.The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer[J].Korean J Intern Med,2013,28(4):449-455.
[33] Sas-Korczynska B,Sokolowski A,Korzeniowski S.The influence of time of radio-chemotherapy and other therapeutic factors on treatment results in patients with limited disease small cell lung cancer[J].Lung Cancer,2013,79(1):14-19.
[34] Xia B,Hong LZ,Cai XW,et al.Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2015,91(3):517-523.
[35] Yee D,Hanson J,Butts C,et al.Phase Ⅰ dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma of the lung[J].Radiother Oncol,2010,96(1):78-83.
[36] Murray N,Coy P,Pater JL,et al.Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer.The National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,1993,11(2):336-344.
[37] Giuliani ME,Lindsay PE,Sun A,et al.Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma[J].Radiother Oncol,2012,102(2):263-267.
[38] Zhang J,Fan M,Liu D,et al.Hypo-or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer[J].Radiat Oncol,2017,12(1):51.
[39] Videtic GM,Stephans KL.The role of stereotactic body radiotherapy in the management of non-small cell lung cancer:an emerging standard for the medically inoperable patient[J]. Curr Oncol Rep,2010,12(4):235-241.
[40] Shioyama Y,Nakamura K,Sasaki T,et al.Clinical results of stereotactic body radiotherapy for Stage Ⅰ small-cell lung cancer:a single institutional experience[J].J Radiat Res,2013,54(1):108-112.
[41] Videtic GM,Stephans KL,Woody NM,et al.Stereotactic body radiation therapy-based treatment model for stage Ⅰ medically inoperable small cell lung cancer[J].Pract Radiat Oncol,2013,3(4):301-306.
[42] Li C,Xiong Y,Zhou Z,et al.Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer:a single-center prospective phase Ⅱ study[J].Med Oncol,2014,31(12):369.
[43] 丁新民,冯华松,伏婷婷,等.紫杉醇顺铂方案联合同步放疗治疗顺铂依托泊苷化疗不敏感局限期小细胞肺癌的临床疗效[J].中国老年学杂志,2016,36(1):344-346.

Research progress in thoracic radiotherapy in limited-disease small cell lung cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Xin LIU,Yuyang ZHANG,Deling ZENG,Xiaoqin LIU,Lu ZHANG,Meiying LI,Hong CHEN,Bangrong CAO,Shiqi MA. Levels of KLRG1 ⁺NK cells in peripheral blood of NSCLC patients and their clinical significances [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 746-754.
[2]	Qiaotong REN,Weihua WU,Xingxiang WANG,Shichao WANG,Yipeng CHENG,Chun LI. Effect of interleukin-17 recepter B gene silencing on proliferation, invasion and apoptosis of lung adenocarcinoma A549 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 738-745.
[3]	Yang LI,Shiyang LI,Hongmei ZHANG,Qianqian LIU,Yubing CHEN. Effect of NGFR gene expression differences on promotion of apoptosis of squamous cell carcinoma and adenocarcinoma cells by PD-1 inhibitor-activated T lymphocytes [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 680-693.
[4]	Lei TANG,Peinan LIN,Ling ZHANG,Haiyan XU,Fengchun ZHANG. Chemotherapy efficacy and plasma drug concentration changes in patient with limited-stage small cell lung cancer complicated with uremia: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1687-1694.
[5]	Xiaoshuang HE,Lina XU,Mei CUI,Yu ZHAO,Bei WANG,Zheng HUANG,Yuchao WANG,Wenyan XIN,Chao WU. Effects of lncRNA DUXAP8 in lung cancer A549 cells-derived exosomes on lung cancer cell growth and its mechnism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 958-967.
[6]	Xingxiang WANG,Ying ZHAO,Qiaotong REN,Hefei WANG,Gang PU,Chun LI. Promotive effect of M2 macrophages on epithelial-mesenchymal transition and cisplatin resistance in non-small cell lung cancer A549 cells by regulating NF-κB signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 642-652.
[7]	Yihui WANG,Qing ZHANG,Yingnan LI,Liping YE. Effect of KIAA1522 on proliferation, migration, and invasion of lung cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 727-739.
[8]	Congcong BAI,Xianlei ZHOU,Zhi ZHANG,Shuang GAO,Xuemei ZHANG. Expression of CSPG4P12 gene in small cell lung cancer tissue and its effect on behaviors of cell biology [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 392-402.
[9]	Bo LIU,Chao SUN,Xu WANG,Kewei MA. Bioinformatics analysis on differentially expressed genes in multiple primary lung cancers based on GEO database [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 437-446.
[10]	Xiaoming WANG,Xueye WANG. Invasive adenocarcinoma of lung complicated with metastatic NUT midline carcinoma of mediastinal lymph node： A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 825-830.
[11]	Aihua REN,Yanbo DONG,Runzhi MIAO,Yujiao LYU,Yanfeng LIU. Effect of ganoderic acid A on glycolysis and its key rate-limiting enzymes of non-small cell lung cancer PC9 cells [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 682-688.
[12]	Yuan WANG,Zhijuan WANG,Mingshu ZHANG,Yihui WANG,Qing ZHANG,Liping YE. Effects of monocyte chemoattractant protein-1 on invasion and migration of lung cancer A549 and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 666-675.
[13]	Zongjun CHEN,Yahong CHEN,Liyun HUANG,Ziying LIANG. Effects of genomic instability and MYC gene mutation of non-small cell lung cancer A549 cells on resistance of gemcitabine [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 355-363.
[14]	Aihua REN,Xinda JU,Aofei LIU,Yongchao LIU,Yanfeng LIU. Effect of ganoderic acid A on proliferation and apoptosis of human non-small cell lung cancer PC-9 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1466-1472.
[15]	Xiaodong GAI,Ying ZHAO,Hefei WANG,Chengyuan HE,Xingxiang WANG,Chun LI. Regulatory effect of FOXP3 on chemosensitivity of non small-cell lung cancer A549 cells to doxorubicin and its mechnism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1161-1167.